Pregabalin Addiction in a Case with Synthetic Cannabinoid Use

G. Koroglu
{"title":"Pregabalin Addiction in a Case with Synthetic Cannabinoid Use","authors":"G. Koroglu","doi":"10.5350/DAJPN2017300108","DOIUrl":null,"url":null,"abstract":"Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures. Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels. Thus, the release of excitatory neuro-transmitters are inhibited and neuronal GABA levels are increased. Pregabalin has also been approved in the European Union for treatment of Generalized Anxiety Disorder. The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration. However, the Food and Drug Administration in the USA (FDA) and European Medicines Agency (EMA) have included pregabalin in the “Schedule V Controlled Substances”. This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5350/DAJPN2017300108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures. Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels. Thus, the release of excitatory neuro-transmitters are inhibited and neuronal GABA levels are increased. Pregabalin has also been approved in the European Union for treatment of Generalized Anxiety Disorder. The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration. However, the Food and Drug Administration in the USA (FDA) and European Medicines Agency (EMA) have included pregabalin in the “Schedule V Controlled Substances”. This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
合成大麻素使用普瑞巴林成瘾1例
普瑞巴林是一种γ -氨基丁酸(GABA)类似物,被批准用于治疗神经性疼痛和部分发作性癫痫。普瑞巴林选择性结合电压门控钙通道的α 2 δ亚基。因此,兴奋性神经递质的释放受到抑制,神经元GABA水平升高。普瑞巴林也被欧盟批准用于治疗广泛性焦虑症。普瑞巴林的抗焦虑作用与苯二氮卓类药物相似,并在给药后迅速发生。然而,美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)已将普瑞巴林列入“附表V受控物质”。这意味着,就像苯二氮卓类药物一样,普瑞巴林被认为是一种滥用可能性较低的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The role of emotional interference on learning in an emotional probabilistic Go/No-Go task Mirtazapine-related manic / hypomanic shift: mini review and case report Psychosurgery and other invasive approaches in treatment-refractory obsessive-compulsive disorder: a brief overview through a case Relationship between depression and anxiety symptoms in studies conducted in Turkey: a meta-analysis study Comorbidity of attention deficit-hyperactivity disorder and substance use disorder
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1